Nikolas von Bubnoff

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Robert Zeiser, Nikolas von Bubnoff, Jason Butler et al. · New England Journal of Medicine · 2020 · 865 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Robert Zeiser, Andreas Burchert, Claudia Lengerke et al. · Leukemia · 2015 · 540 citations · Full text

Medicine, Clinical Sciences, Immunology +16

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

Nikolas von Bubnoff, Folker Schneller, Christian Peschel et al. · The Lancet · 2002 · 462 citations

Medicine, Hematology, Oncology +15

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

Silvia Spoerl, Nimitha R. Mathew, Michael Bscheider et al. · Blood · 2014 · 394 citations

Life Sciences, Immunology, Pharmacotherapy +14